Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:


Last Updated: November 29, 2021

DrugPatentWatch Database Preview

Patent: 8,367,699

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 8,367,699
Abstract: The present invention provides a compound selected from compounds of formula (A) as ligand binding to the HDM2 protein, inducing apoptosis and inhibiting proliferation, and having therapeutic utility in cancer therapy and prevention. Compounds of formula (A) can be used as therapeutics for treating stroke, myocardial infarction, ischemia, multi-organ failure, spinal cord injury, Alzheimer\'s Disease, injury from ischemic events and heart valvular degenerative disease. Moreover, compounds of formula (A) can be used to decrease the side effects from cytotoxic cancer agents, radiation and to treat viral infections. ##STR00001##
Inventor(s): Weber; Lutz (Germering, DE), Khazak; Vladimir (Brooklyn, NY), Ross; Gunther (Munich, DE), Kalinski; Cedric (Munich, DE), Burdack; Christoph (Munich, DE)
Assignee: NexusPharma, Inc. (Langhorne, PA)
Application Number:12/441,266
Patent Claims:see list of patent claims

Details for Patent 8,367,699

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 1986-06-04 ⤷  Try it Free 2026-09-15
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 ⤷  Try it Free 2026-09-15
Clinigen, Inc. PROLEUKIN aldesleukin For Injection 103293 1992-05-05 ⤷  Try it Free 2026-09-15
Amgen, Inc. NEUPOGEN filgrastim Injection 103353 1991-02-20 ⤷  Try it Free 2026-09-15
Amgen, Inc. NEUPOGEN filgrastim Injection 103353 2000-06-28 ⤷  Try it Free 2026-09-15
Partner Therapeutics, Inc. LEUKINE sargramostim For Injection 103362 1991-03-05 ⤷  Try it Free 2026-09-15
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.